오름테라퓨틱

475830KOSDAQ기초 의약물질 제조업

42.1 / 100

Reference Date: 2026-04-13

Financial Score7.5 / 40

News Sentiment14.6 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 38.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Orm Therapeutics is a clinical-stage biotech company developing antibody-based targeted protein degradation (TPD²®) therapies to treat cancer. Its key candidates, ORM-5029 and ORM-1153, target HER2-positive breast cancer and hematologic malignancies, with ORM-5029 in Phase 1 trials and ORM-1153 preparing for IND submission in 2026. TPD² combines ADC technology to deliver protein degraders selectively to cancer cells, minimizing off-target effects and enhancing therapeutic efficacy.

Number of Employees

21people

Average Salary

174.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

14.00Industry Average 2.030.0Point

6.9x industry avg (risky)

ROE

-33.22Industry Average -4.293.5Point

7.7x industry avg (excellent)

Debt Ratio

17.44Industry Average 6.610.0Point

2.6x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼99.9% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼521.0% (1-year basis)

ROE Trend

0.0 / 4

Detailed News Sentiment

7 totalPositive 1Neutral 2Negative 0Average Sentiment Score 70

Positive
이승주 "올해 혈액암 신약 임상 착수…기존 치료제 한계 극복할 것"
오름테라퓨틱은 자체 설계한 항체접합분해제(DAC) 신약 후보물질 'ORM-1153'의 혈액암 임상에 올해 착수할 예정이며, 기존 치료제의 한계를 극복할 것으로 기대됩니다.
Neutral
“K바이오, 세계가 주목…하지만 아직 ‘먹거리’ 부족하다” [EW바이....
K바이오가 글로벌 투자자와 제약사로부터 주목받고 있으나, 아직 '먹거리'가 부족하다는 전문가들의 진단이 나왔습니다.
Neutral
K바이오에 '봄바람'… 뚝심의 기업가정신으로 끝까지 가보자
K바이오 전문가들은 최근 '이스트웨스트 바이오파마 서밋 서울'을 통해 K바이오의 글로벌 경쟁력을 확인했으며, 임상 속도를 내 '먹거리'를 창출해야 한다고 강조했습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (54%)

Current 86,300Won52-week high 143,70052-week low 17,010

1-month return0.0Point

1m -38.14% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

12 totalPositive 0Neutral 12Negative 0

Neutral[기재정정]주식매수선택권행사2026-04-08
Neutral주식매수선택권행사2026-04-01
Neutral주식등의대량보유상황보고서(일반)2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30